Use this map to plan your route and discover just how close you are to this enchanting destination. So grab your camera, put ...
The Opti-GAIN study from Complement Therapeutics is assessing the safety, tolerability, and preliminary efficacy in GA secondary to age-related macular degeneration (AMD) of CTx001. A first-in-human ...
Chugai Pharmaceutical Co ((CHGCF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...
Please provide your email address to receive an email when new articles are posted on . The current state of treatment for geographic atrophy is marked by two approved therapies that slow GA ...
--- The United States FDA Clears Initiation of a Phase II Efficacy Trial in Immunoglobulin A Nephropathy (IgAN) Patients: a renal disorder CLEVELAND, Dec. 02, 2024 (GLOBE NEWSWIRE) -- NovelMed is ...
Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. Article Views are the COUNTER-compliant sum of full text article downloads since ...
Annexon, Inc. (Nasdaq: ANNX) today reported results from the Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) healthy volunteer study of ANX1502, a first-in-kind oral, selective ...
Copyright: Published by Elsevier Ltd. The complement system is recognised as a protector against blood-borne pathogens and a controller of immune system and tissue ...
With the recent FDA approvals of pegcetacoplan (SYFOVRE, Apellis Pharmaceuticals) and avacincaptad pegol (IZERVAY, Astellas Pharmaceuticals), modulation of the complement system has emerged as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results